| [1] |
Gionchetti P, Calafiore A, Riso D, et al. The role of antibiotics and probiotics in pouchitis [J]. Ann Gastroenterol, 2012, 25(2): 100-105.
|
| [2] |
Madden MV, Farthing MJ, Nicholls RJ. Inflammation in ileal reservoirs: ′Pouchitis′ [J]. GUT, 1990, 31(3): 247-249.
|
| [3] |
Nicholls RJ, Belliveau P, Neill M, et al. Restorative proctocolectomy with ileal reservoir: A pathophysiological assessment [J]. GUT, 1981, 22(6): 462-468.
|
| [4] |
Ruseler-van EJ, Schouten WR, van Lieshout LM. Pouchitis: Result of microbial imbalance? [J]. GUT, 1994, 35(5): 658-664.
|
| [5] |
Iwaya A, Iiai T, Okamoto H, et al. Change in the bacterial flora of pouchitis [J]. Hepatogastroenterology, 2006, 53(67): 55-59.
|
| [6] |
Falk A, Olsson C, Ahrne S, et al. Ileal pelvic pouch microbiota from two former ulcerative colitis patients, analysed by DNA-based methods, were unstable over time and showed the presence of Clostridium perfringens [J]. Scand J Gastroenterol, 2007, 42(8): 973-985.
|
| [7] |
Zella GC, Hait EJ, Glavan T, et al. Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis [J]. INFLAMM BOWEL DIS, 2011, 17(5): 1092-1100.
|
| [8] |
McLaughlin SD, Walker AW, Churcher C, et al. The bacteriology of pouchitis: A molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing [J]. ANN SURG, 2010, 252(1): 90-98.
|
| [9] |
Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults [J]. GUT, 2011, 60(5): 571-607.
|
| [10] |
Gionchetti P, Rizzello F, Venturi A, et al.Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial [J]. GASTROENTEROLOGY, 2000, 119(2): 305-309.
|
| [11] |
Islam SU. Clinical uses of probiotics [J]. Medicine(Baltimore), 2016, 95(5): e2658.
|
| [12] |
Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial [J]. GASTROENTEROLOGY, 2003, 124(5): 1202-1209.
|
| [13] |
Pronio A, Montesani C, Butteroni C, et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells [J]. INFLAMM BOWEL DIS, 2008, 14(5): 662-668.
|
| [14] |
Gosselink MP, Schouten WR, van Lieshout LM, et al. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG [J]. DIS COLON RECTUM, 2004, 47(6): 876-884.
|
| [15] |
Yasueda A, Mizushima T, Nezu R, et al. The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis [J]. SURG TODAY, 2016, 46(8): 939-949.
|
| [16] |
Elahi B, Nikfar S, Derakhshani S, et al. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: A meta-analysis of controlled clinical trials [J]. Dig Dis Sci, 2008, 53(5): 1278-1284.
|
| [17] |
Singh S, Stroud AM, Holubar SD, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis [J]. Cochrane Database Syst Rev, 2015, 23(11): D1176.
|
| [18] |
Bengtsson J, Adlerberth I, Ostblom A, et al.Effect of probiotics(Lactobacillus plantarum 299 plus Bifidobacterium Cure21)in patients with poor ileal pouch function: A randomised controlled trial [J]. Scand J Gastroenterol, 2016, 51(9): 1087-1092.
|
| [19] |
Gionchetti P, Rizzello F, Morselli C, et al.High-dose probiotics for the treatment of active pouchitis [J]. DIS COLON RECTUM, 2007, 50(12): 2075-2082, 2082-2084.
|
| [20] |
Laake KO, Bjorneklett A, Aamodt G, et al. Outcome of four weeks’ intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis [J]. Scand J Gastroenterol, 2005, 40(1): 43-51.
|
| [21] |
Tomasz B, Zoran S, Jaroslaw W, et al. Long-term use of probiotics Lactobacillus and Bifidobacterium has a prophylactic effect on the occurrence and severity of pouchitis: A randomized prospective study [J]. BIOMED RES INT, 2014, 2014: 208064.
|
| [22] |
Kuisma J, Mentula S, Jarvinen H, et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora [J]. Aliment Pharmacol Ther, 2003, 17(4): 509-515.
|
| [23] |
Uchino M, Ikeuchi H, Matsuoka H, et al. Topical tacrolimus therapy for antibiotic-refractory pouchitis [J]. DIS COLON RECTUM, 2013, 56(10): 1166-1173.
|
| [24] |
Wall GC, Schirmer LL, Anliker LE, et al. Pharmacotherapy for acute pouchitis [J]. ANN PHARMACOTHER, 2011, 45(9): 1127-1137.
|
| [25] |
Mimura T, Rizzello F, Helwig U, et al.Once daily high dose probiotic therapy(VSL#3)for maintaining remission in recurrent or refractory pouchitis [J]. GUT, 2004, 53(1): 108-114.
|
| [26] |
Holubar SD, Cima RR, Sandborn WJ, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis [J]. Cochrane Database Syst Rev, 2010, 16(6): D1176.
|
| [27] |
Shen B, Brzezinski A, Fazio VW, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: Experience in clinical practice [J]. Aliment Pharmacol Ther, 2005, 22(8): 721-728.
|
| [28] |
Kanauchi O, Matsumoto Y, Matsumura M, et al. The beneficial effects of microflora, especially obligate anaerobes, and their products on the colonic environment in inflammatory bowel disease [J]. Curr Pharm Des, 2005, 11(8): 1047-1053.
|
| [29] |
Stephani J, Radulovic K, Niess JH. Gut microbiota, probiotics and inflammatory bowel disease [J]. Arch Immunol Ther Exp(Warsz), 2011, 59(3): 161-177.
|
| [30] |
Mack DR, Ahrne S, Hyde L, et al. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro [J]. GUT, 2003, 52(6): 827-833.
|
| [31] |
Caballero-Franco C, Keller K, De Simone C, et al. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells [J]. Am J Physiol Gastrointest Liver Physiol, 2007, 292(1): G315-G322.
|
| [32] |
Veerappan GR, Betteridge J, Young PE. Probiotics for the treatment of inflammatory bowel disease [J]. Curr Gastroenterol Rep, 2012, 14(4): 324-333.
|
| [33] |
Ukena SN, Singh A, Dringenberg U, et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity [J]. PLOS ONE, 2007, 2(12): e1308.
|
| [34] |
Karczewski J, Troost FJ, Konings I, et al. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier [J]. Am J Physiol Gastrointest Liver Physiol, 2010, 298(6): G851-G859.
|
| [35] |
Kotzampassi K, Giamarellos-Bourboulis EJ. Probiotics for infectious diseases: More drugs, less dietary supplementation [J]. Int J Antimicrob Agents, 2012, 40(4): 288-296.
|
| [36] |
Collado MC, Meriluoto J, Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus [J]. LETT APPL MICROBIOL, 2007, 45(4): 454-460.
|
| [37] |
Veerappan GR, Betteridge J, Young PE. Probiotics for the treatment of inflammatory bowel disease [J]. Curr Gastroenterol Rep, 2012, 14(4): 324-333.
|
| [38] |
Mack DR. Probiotics in inflammatory bowel diseases and associated conditions [J]. NUTRIENTS, 2011, 3(2): 245-264.
|
| [39] |
Macho FE, Pot B, Grangette C. Beneficial effect of probiotics in IBD: Are peptidogycan and NOD2 the molecular key effectors? [J]. Gut Microbes, 2011, 2(5): 280-286.
|
| [40] |
Prisciandaro L, Geier M, Butler R, et al. Probiotics and their derivatives as treatments for inflammatory bowel disease [J]. INFLAMM BOWEL DIS, 2009, 15(12): 1906-1914.
|
| [41] |
Collado MC, Meriluoto J, Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus [J]. LETT APPL MICROBIOL, 2007, 45(4): 454-460.
|
| [42] |
Stephani J, Radulovic K, Niess JH. Gut microbiota, probiotics and inflammatory bowel disease [J]. Arch Immunol Ther Exp(Warsz), 2011, 59(3): 161-177.
|